FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up from Dual Therapy Stratified by Exacerbations and Prior Dual Therapy: A Subgroup Analysis of a Comparative Effectiveness Study
Patients newly initiating FF/UMEC/VI following prior treatment with ICS/LABA or LAMA/LABA experienced a significantly lower rate of moderate-severe COPD exacerbations than those newly initiating BUD/GLY/FORM irrespective of number of prior exacerbations or prior dual therapy class.
Authors
- Stephen Weng (ORCID: https://orcid.org/0000-0002-5281-9590)
- Anurita Majumdar (ORCID: https://orcid.org/0000-0002-8047-9378)
- Valentina Di Boscio
- Rosirene Paczkowski (ORCID: https://orcid.org/0009-0001-7151-4311)
- F. Laliberté
- Stephen G. Noorduyn (ORCID: https://orcid.org/0000-0002-5936-5579)
- Guillaume Germain
- Olivier Le Rouzic
- David Mannino
- Jadwiga A. Wedzicha
Institutions
- University of Kentucky (US)
- Université de Lille (FR)
- Age UK (GB)
- Centre Hospitalier Universitaire de Lille (FR)
- Center for Infection and Immunity of Lille (FR)
- Health Outcomes Solutions (United States) (US)
- GlaxoSmithKline (Canada) (CA)
- Group for Research in Decision Analysis (CA)
- COPD Foundation (US)
- GlobalFoundries (Singapore) (SG)
- Imperial College London (GB)
- McMaster University (CA)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1007/s12325-025-03470-7
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00